News
News Release
Cyclomedical Applications Group, LLC
Expands its Resources
Contact: James F. Lamb, Ph.D.
+1-865-670-9021
jlamb@cyclomedical.com
KNOXVILLE, Tennessee,
2006 May 4—Cyclomedical Applications Group, in response to its expanding business, has added another Associate to its team of experts who provide services to PET (positron emission tomography) accelerator operations.
Christopher A. Vascoe has been a radiochemist with the Biomedical Research Foundation for more than five years. He is accomplished at managing, producing and developing radiopharmaceutical production and distribution and has fabricated synthesis units and cyclotron targets. He is also able to optimize existing synthesizer and target systems. He is experienced in GMP compliance for both clinical and research operations and has designed GMP laboratories and 797 pharmacies. He is also responsible for NDA’s for FDG and NaF products. Chris has also worked as an analytical chemist, a formulation chemist and a microbiologist—in both production and R&D settings—and is able to perform process, cleaning and method validations. He has degrees in Biochemistry and Electromechanical Technology.
Dr. James Lamb, President of Cyclomedical, stated, “I was extremely impressed with the spectacular performance of Chris on a radiochemistry challenge with one of our clients, so I invited him to join our team. We are proud to welcome him as an Associate of Cyclomedical, and he will be a valuable resource for our customers.”
Cyclomedical Applications Group is an organization of experienced radiopharmaceutical experts serving the nuclear medicine industry, especially owners and operators of medical accelerators dedicated to the production of positron emitting radioisotopes. It works primarily with facilities producing and distributing F-18 FDG—the most widely used positron-emitting radiopharmaceutical in PET scanning.
Consulting services offered by the company range from short-term consultation to longer-term retainer arrangements and assistance with regulatory agencies as well as cyclotron operation and FDG production problems. Contract management services range from full responsibility for a cyclotron/FDG production facility to a monitoring posture in support of an in-place management team.
Cyclomedical’s goal is to provide a full range of support expertise including FDG market research and development, facility financing, facility planning and operation, licensing and safety, and FDA regulatory issues. The company currently has operational responsibility for several cyclotron/FDG facilities and is providing consultation services to a number of accelerator operating companies. For more information, see the Cyclomedical web site at www.cyclomedical.com.